Effects of add-on therapy consisting of a selective mineralocorticoid receptor blocker on arterial stiffness in patients with uncontrolled hypertension

Internal Medicine

Volumn 54, Issue 13, 2015, Pages 1583-1589

  Shibata, Takahiro ^a   Tsutsumi, Joshi ^a   Hasegawa, Jun ^a   Sato, Nobutaka ^a   Murashima, Eitatsu ^a   Mori, Chikara ^a   Hongo, Kenichi ^b   Yoshimura, Michihiro ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Arterial stiffness; Calcium channel blocker; Cardio ankle; Mineralocorticoid receptor blocker

Indexed keywords

AMLODIPINE; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; EPLERENONE; NIFEDIPINE; POTASSIUM; ANTIHYPERTENSIVE AGENT; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; AGED; ARTERIAL STIFFNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CARDIO ANKLE VASCULAR INDEX; CARDIOVASCULAR DISEASE ASSESSMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE ESCALATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MALE; PULSE WAVE; RETROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; BLOOD PRESSURE; DRUG EFFECTS; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; HYPERTENSION; MALE; RECEPTORS, MINERALOCORTICOID; RETROSPECTIVE STUDIES; SPIRONOLACTONE; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84936150299     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.54.3427     Document Type: Article

References (28)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717, 1999.
2. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309-1321, 2003.
3. Zannad F, Mc Murray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11-21, 2011.
4. Takai S, Jin D, Muramatsu M, et al. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46: 1135-1139, 2005.
5. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283: H1802-H1810, 2002.
6. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143: 4828-4836, 2002.
7. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43: 1252-1257, 2004.
8. Lal A, Veinot JP, Leenen FH. Prevention of high salt diet-induced cardiac hypertrophy and fibrosis by spironolactone. Am J Hypertens 16: 319-323, 2003.
9. Savoia C, Touyz RM, Amiri F, Schiffrin EL. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 51: 432-439, 2008.
10. White WB, Duprez DD, Hillaire RS, et al. Effects of the selective aidosterone blocker eplerenone versus the calcium antagonisit amlodipine in sysytolic hypertension. Hypertension 41: 1021-1026, 2003.
11. Boesby L, Elung-Jensen T, Strandgaard S, Kamper AL. Eplerenone attenuates pulse wave refletion in chronic kidney disease stage 3-4 a randomized controlled study. PLoS One 8: 1-9, 2013.
12. Hwang MH, Yoo JK, Luttrell M, et al. Role of mineralocorrticoid receptors in arterial stiiffness in human aging. Exp Gerontol 48: 701-704, 2013.
13. Delyani JA, Rocha R, Cook CS, et al. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc Drug Rev 19: 185-200, 2001.
14. Mc Mahon EG. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr Opin Pharmacol 1: 190-196, 2001.
15. The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Hypertens Res 32: 4-107, 2009.
16. Yoshimura S, Hasegawa M, Arai C, Abe M, Aizawa Y. Aortic pulse wave velocity and arteriosclerosis. Rinsho Byori (Jpn J Clin Pathol) 21: 79-86, 1973 (in Japanese).
17. Yambe T, Yoshizawa M, Saijo Y, et al. Brachio-ankle pulse wave velocity and cardio-ankle vascular index (CAVI). Biomed Pharmacother 58 (Suppl 1): S95-S98, 2004.
18. Shirai K, Utino J, Otsuka K, Takata M. A novel blood pressureindependent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 13: 101-107, 2006.
19. Ibata J, Sasaki H, Kakimoto T, et al. Cardio-ankle vascular index measures arterial wall stiffness independent of blood pressure. Diabetes Res Clin Pract 80: 265-270, 2008.
20. Suzuki J, Iwai M, Mogi M, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxigative stress and inflammation. Arterioscler Thromb Biol 26: 917-921, 2006.
21. Qureshi G, Brown R, Salciccioli L, et al. Relationship between aortic atherosclerosis and non-invasive measures of arterial stiffness. Atherosclerosis 195: e190-e194, 2007.
22. Duprez DA, Cohn JN. Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep 9: 139-144, 2007.
23. Mahmud A, Feely J. Arterial stiffness and the renin-angiotensinaldosterone system. J Renin Angiotensin Aldosterone Syst 5: 102-108, 2004.
24. Zhang Q, Saito Y, Naya N, et al. The specific minerarlcorticoid receptor blocker eplerenone attenuates left ventricular remodeling in mice lacking the gene encoding guanylyl cyclase A. Hypertens Res 31: 1251-1256, 2008.
25. Macdonald JE, Kennedy N, Struthers AD. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already takaing optimal treatment. Heart 90: 765-770, 2004.
26. Kimura M, Ogawa H, Wakeyama T, et al. Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling n patients with heart failure. J Cardiol 57: 208-211, 2011.
27. Aritomi S, Wagatsuma H, Numata T, et al. Expression of N-type calcium channels in human adrenocortical cells and their contribution to corticosteroid synthesis. Hypertens Res 34: 193-201, 2011.
28. Okayama S, Imagawa K, Naya N, et al. Blocking T-type Ca2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens Res 29: 493-497, 2006.